Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
With a median follow-up of 38 months, these early results suggest that focal LDR brachytherapy for low-intermediate risk, single-lesion, imaging-visible PCa demonstrates satisfactory oncological control. However, further follow-up is needed to assess long-term oncological outcomes.
Authors
- Mohammadmehdi Adhami (ORCID: https://orcid.org/0000-0002-8326-6175)
- Lloyd M. L. Smyth (ORCID: https://orcid.org/0000-0002-6675-5807)
- Cate Davey
- Jeremy Grummet (ORCID: https://orcid.org/0000-0003-4382-8169)
- Elliot Anderson (ORCID: https://orcid.org/0000-0002-3658-2773)
- Andrew See
- Jeremy Cheng
- Richard O'Sullivan
- Nathan Lawrentschuk
- Thang Nguyen
- Andrew Ryan
Institutions
- The Royal Melbourne Hospital (AU)
- Cancer Council Victoria (AU)
- The Alfred Hospital (AU)
- Victorian Comprehensive Cancer Centre (AU)
- Monash University (AU)
Publication Details
- Journal
- BJUI Compass
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/bco2.70129
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Société Internationale D'Urologie
- Australian Government
- Monash University